Monoclonal antibodies used as prophylactic, therapeutic and diagnostic agents

被引：1

作者：

Chakhtoura, Marita ^{[1
]}

Abdelnoor, Alexander M. ^{[1
]}

机构：

[1] Amer Univ Beirut, Dept Microbiol & Immunol, Fac Med, Beirut 11972020, Lebanon

来源：

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY | 2010年 / 32卷 / 04期

关键词：

Monoclonal antibodies; preparation; mechanism of action; uses; drawbacks; COLON-CANCER; PREVENTION; REJECTION; IMMUNOPURIFICATION; TRANSPLANTATION; CHEMOTHERAPY; INFECTION; RITUXIMAB; LYMPHOMA; DISEASE;

D O I：

10.3109/08923971003646597

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Monoclonal antibodies can be of mouse, part mouse part human (chimeric, humanized), or of human origin. Their preparation involves hybridoma, gene cloning, gene recombination, phage display, and gene transfection techniques. The preparation, mechanism of action, uses, and possible adverse effects of most of the available monoclonal antibodies used as prophylactic, therapeutic, and diagnostic agents are reviewed.</.

引用

页码：533 / 542

页数：10

共 50 条

[31] From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal [J].

Ribatti, Domenico .

IMMUNOLOGY LETTERS, 2014, 161 (01) :96-99

[32] Therapeutic monoclonal antibodies in hematologic malignancies: Biological responses and safety [J].

Rate, R. ;

Ludwig, W. -D. .

ANNALS OF HEMATOLOGY, 2006, 85 :42-46

[33] Novel strategies in systemic and local administration of therapeutic monoclonal antibodies [J].

Prasnikar, Monika ;

Ziberna, Maja Bjelosevic ;

Matjaz, Mirjam Gosenca ;

Grabnar, Pegi Ahlin .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 667

[34] Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors [J].

Ashley, DM ;

Batra, SK ;

Bigner, DD .

JOURNAL OF NEURO-ONCOLOGY, 1997, 35 (03) :259-273

[35] Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors [J].

David M. Ashley ;

Surinder K. Batra ;

Darell D. Bigner .

Journal of Neuro-Oncology, 1997, 35 :259-273

[36] Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach [J].

Baertsch, Marc-Andrea ;

Hundemer, Michael ;

Hillengass, Jens ;

Goldschmidt, Hartmut ;

Raab, Marc S. .

HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) :258-261

[37] A safety review of current monoclonal antibodies used to treat multiple sclerosis [J].

Costa, Gloria Dalla ;

Comi, Giancarlo .

EXPERT OPINION ON DRUG SAFETY, 2023, 22 (11) :1011-1024

[38] Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations [J].

Coulson, A. ;

Levy, A. ;

Gossell-Williams, M. .

WEST INDIAN MEDICAL JOURNAL, 2014, 63 (06) :650-654

[39] Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new? [J].

Mir, Olivier ;

Broutin, Sophie ;

Desnoyer, Aude ;

Delahousse, Julia ;

Chaput, Nathalie ;

Paci, Angelo .

EUROPEAN JOURNAL OF CANCER, 2020, 128 :103-106

[40] Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model [J].

Zeitlin, Larry ;

Bohorov, Ognian ;

Bohorova, Natasha ;

Hiatt, Andrew ;

Kim, Do H. ;

Pauly, Michael H. ;

Velasco, Jesus ;

Whaley, Kevin J. ;

Barnard, Dale L. ;

Bates, John T. ;

Crowe, James E., Jr. ;

Piedra, Pedro A. ;

Gilbert, Brian E. .

MABS, 2013, 5 (02) :263-269

← 1 2 3 4 5 →